基本信息 产品详情 公司简介 推荐产品
网站主页 化工产品目录 生物化工 生化试剂 BET抑制剂 Pelabresib (CPI-0610)
  • aladdin 阿拉丁 P413856 Pelabresib (CPI-0610) 1380087-89-7 98%

aladdin 阿拉丁 P413856 Pelabresib (CPI-0610) 1380087-89-7 98%

Pelabresib (CPI-0610)
1380087-89-7
746.90 5mg 起订
1112.90 10mg 起订
2779.90 25mg 起订
上海 更新日期:2025-05-16

上海阿拉丁生化科技股份有限公司

VIP3年
联系人:阿拉丁客服
电话:400-6206333拨打
手机:13167063860 拨打
邮箱:anhua.mao@aladdin-e.com

产品详情:

中文名称:
Pelabresib (CPI-0610)
英文名称:
Pelabresib (CPI-0610)
CAS号:
1380087-89-7
品牌:
阿拉丁
产地:
上海
保存条件:
-20°C储存
纯度规格:
Moligand™, ≥98%
产品类别:
小分子和化合物库 配体家族
分子式:
C20H16ClN3O2
分子量:
365.81
运输条件:
超低温运输
产品规格:
25mg、5mg、10mg
货号:
P413856
是否进口:

中文名:Pelabresib (CPI-0610)

英文名:Pelabresib (CPI-0610)

纯度:Moligand™,≥98%

货号:P413856

Cas号:1380087-89-7

存储温度:-20°C储存

运输条件:超低温运输

产品介绍:

Information

Pelabresib (CPI-0610) Pelabresib (CPI-0610) is a potent and selective benzoisoxazoloazepine BET bromodomain inhibitor with an IC50 of 39 nM for BRD4-BD1 in TR-FRET assay and currently undergoing human clinical trials for hematological malignancies. CPI-0610 inhibits the expression of Nuclear receptor binding SET domain protein 3 (NSD3) target genes.


Targets

BRD4-BD1 (Cell-free assay); MYC (in MV-4-11 cells) 39 nM; 180 nM(EC50)


In vitro

CPI-0610 inhibits MM(multiple myeloma) cell growth in the presence of cytokines and when co-cultured with bone marrow stromal cells. CPI-0610 induces apoptosis and G1 cell cycle arrest associated with MYC downregulation. However, protein levels of BCL2, NF-κB and MCL1 remain unchanged in MM cells upon BET inhibition. CPI-0610 suppresses Ikaros and IRF4 expression at the levels of both transcription and protein in MM cells.


In vivo

In a mouse xenograft model using MV-4-11 acute myeloid leukemia cells, MYC mRNA levels of CPI-0610-treated mice were substantially reduced at 4 h compared to the vehicle control and recovered toward the control level at the later time points, which corresponded with decreasing free concentrations of compound in plasma. BET bromodomain inhibition by CPI-01610 resulted in substantial suppression oftumor growth over the time period examined (41%, 80%, and 74% tumor growth inhibition, respectively), without any significant body weight loss in the animals. On the basis of an acceptable toxicity profile in rat and dog, A common set of toxicities was observed in both species: lymphoid depletion; hypocellularity of the bone marrow with associated anemia and thrombocytopenia; GI mucosal atrophy, erosion, and ulceration; degeneration of the testicular seminiferous epithelium; and mild to moderate hyperglycemia. These toxicities is reversible.


Cell Research(from reference)

Cell lines:MV-4-11 cells 

Incubation Time:4 h 


查看阿拉丁官网此产品相关对应页面:https://www.aladdin-e.com/zh_cn/P413856.html


培拉贝尼 (CPI-0610);Q27076907 ; SCHEMBL15926539 ; EX-A1612

公司简介

上海阿拉丁生化科技股份有限公司是A股上市公司((股票代码:688179),专注于科研试剂的研发、生产和销售,已陆续建立多个工厂和研发中心。作为领军企业,阿拉丁始终坚持质量第一,连续13年被评为“最受欢迎试剂品牌”。 阿拉丁目前常备库存试剂产品品种超过7万种,SKU总数超过46万,产品线涵盖了化学试剂、生化试剂、药靶配体、蛋白质和抗体等多个领域,是国内少数化学试剂到生物试剂全面发展的国产试剂品牌,产品同步发布在我们国内外电商平台。

成立日期 (17年)
注册资本 14130.676万人民币
员工人数 500人以上
年营业额 ¥ 1亿以上
经营模式 工厂,试剂
主营行业 生物化工,化学试剂

Pelabresib (CPI-0610)相关厂家报价

内容声明
拨打电话 立即询价